Navlimetostat is an investigational new drug that is being evaluated by Mirati Therapeutics abd Bristol-Myers Squibb for the treatment of adenocarcinoma. It is a PRMT5 protein inhibitor.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.